Loading...
Loading...
BioLineRx
BLRX, a biopharmaceutical development
company, announced today that it has signed an out-licensing agreement
with Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), the
leading Chinese pharmaceutical company in the liver disease therapeutic
area, for the development and commercialization of BL-8030, an orally
available treatment for the Hepatitis C virus (HCV).
Under the terms of the agreement, BioLineRx will grant CTTQ exclusive
rights to develop, manufacture and commercialize BL-8030 in China and
Hong Kong. CTTQ will pay BioLineRx an upfront license fee, plus future
development, regulatory and commercialization milestones, for a total
potential deal value of approximately $30 million. In addition,
BioLineRx has the right to receive high single-digit royalties on future
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in